Abdominal pain and Wegovy: what the clinical evidence tells us

What the trial data actually showed about abdominal discomfort

The STEP 1 trial (68 weeks, 1,961 adults with obesity, semaglutide 2.4 mg versus placebo) remains the foundational evidence for Wegovy's side-effect profile. Nausea led the list, but abdominal pain, diarrhoea and constipation clustered close behind. Crucially, the trial showed a clear temporal pattern: events were concentrated in the first four to eight weeks and in the days immediately following each dose increase. Participants who completed the full titration schedule and reached the 2.4 mg maintenance dose reported markedly fewer GI complaints than they had during earlier steps.

Why does this happen? Semaglutide activates GLP-1 receptors throughout the gut, slowing how quickly the stomach empties food into the small intestine. That slower transit is partly responsible for the appetite-lowering effect, and it is also the direct reason the gut can feel crampy, full or unsettled while it adapts. Eating more slowly, taking smaller portions and avoiding very fatty meals during the first weeks can make a meaningful difference. Our clinical team discusses this during every consultation; you can read more about how the medicine works on the Wegovy treatment page.

For most people in the trials, abdominal discomfort did not cause them to withdraw from the study. The subset who did discontinue due to GI events was small. That context matters, but it does not mean discomfort should be dismissed or pushed through without support.

The red flag that must not be ignored: acute pancreatitis

On 29 January 2026 the MHRA published a Drug Safety Update for GLP-1 receptor agonists (including semaglutide) specifically addressing acute pancreatitis. The regulator confirmed pancreatitis as a known but infrequent side effect and set out a clear clinical signal: report any suspected reaction via the MHRA Yellow Card scheme and seek urgent medical attention for severe, persistent stomach pain that radiates toward the back, with or without vomiting.

This is categorically different from the everyday abdominal cramping most people experience during dose titration. Pancreatic pain tends to be intense, does not improve with position changes and typically arrives suddenly. If there is any doubt, the right move is to stop taking the pen and contact 111 or go to A&E, not to wait and see whether the next day brings improvement. Our prescribers ask about this at every clinical review, and if you are already on treatment with us and have concerns, the aftercare team is available seven days a week.

A history of pancreatitis is one of the factors a prescriber will ask about before recommending semaglutide. It does not automatically rule out treatment, but it changes the risk-benefit calculation significantly.

Distinguishing ordinary discomfort from cramping that needs attention

Not every bout of stomach pain during Wegovy treatment carries the same weight. The NHS medicines page for semaglutide sets out a practical framework: common side effects such as nausea, bloating and abdominal cramps are expected, particularly early on, and self-resolve for most people. Specific symptoms that warrant prompt medical contact include signs of a serious allergic reaction, jaundice or upper-right abdominal pain (suggesting gallbladder involvement), and the pancreatic pain pattern described above.

Gallstones are worth mentioning separately. Rapid weight loss of any cause increases gallstone risk, and there is trial-level evidence linking semaglutide use to a small increase in biliary events. Characteristically this produces pain in the upper-right abdomen, sometimes radiating to the right shoulder, and often arriving after eating. If this pattern sounds familiar, speak to a GP or contact your prescribing service. You can also explore how related symptoms such as abdominal cramps or gas pain present differently from these more serious signals.

Abdominal pain that persists beyond the first two weeks at a stable dose, that wakes you at night, or that is accompanied by fever or yellowing of the skin warrants prompt review. Do not adjust your dose yourself in response to pain; that decision sits with your prescriber and the guidance in your patient information leaflet.

Managing abdominal discomfort day to day

Several practical adjustments reduce the intensity and frequency of GI side effects without requiring a dose change. Eating smaller, lower-fat meals at a measured pace is consistently reported to help. Staying well hydrated matters too, particularly if nausea is discouraging fluid intake. Some people find that taking paracetamol helps with cramp-type pain in the first few days after a new pen, but any ongoing use of pain relief for GI symptoms should be mentioned to your prescriber, because some analgesics can themselves irritate the stomach. If you are also noticing soreness or irritation around the injection site, our page on skin pain with Wegovy covers what is normal and when it is worth raising with your prescribing team.

Timing sometimes plays a role in how severe the first day or two after injection feels. People who inject on a Monday and then have a demanding week in front of them occasionally find a quieter day, perhaps over a long weekend, reduces the impact of early nausea on their routine. That said, consistency of day matters more than the specific day chosen; switching the day of injection regularly can disrupt tolerance.

If you are considering Wegovy and want to understand the full picture of what treatment involves day to day, the semaglutide overview covers the mechanism, the titration schedule and what to expect across the first months. For context on what the private treatment pathway looks like and how pricing works, the guide on where to buy Wegovy in the UK is a useful next step. When you are ready to discuss your own situation with a clinician, you can speak to our prescribers through a free consultation, reviewed the same day by a registered Independent Prescriber, not a screening algorithm.